Early clinical trials designed to treat Parkinson's disease by transplantation of fetal tissue
containing dopamine neuron precursors yielded promising results, but the approach retains …

Parkinson disease (PD) is characterized by loss of the A9 nigral neurons that provide
dopaminergic innervation to the striatum. This discovery led to the successful instigation of …

Motor dysfunctions in Parkinson's disease are considered to be primarily due to the
degeneration of dopaminergic neurons in the substantia nigra pars compacta …

Transplantation of human fetal dopamine (DA) neurons to patients with Parkinson's disease
(PD) has given proof of the principle that new neurons can survive for at least a decade, and …

The ability to successfully replace lost nigral dopaminergic neurons in Parkinson's disease
(PD) has been clearly shown with fetal ventral mesencephalic transplants, albeit …

Treating neurodegenerative diseases with cell transplantation has been within reach since
the first pioneering clinical trials in which dopamine neuron progenitors from the fetal brain …

Current approaches to cell replacement therapy in Parkinson's disease are strongly focused
on the dopamine system, with the view that restoring dopaminergic inputs in a localized and …

Importance Recent advances in stem cell technologies have rekindled an interest in the use
of cell replacement strategies for patients with Parkinson disease. This study reports the very …

Cell replacement therapy in Parkinson's disease (PD) has so far been based on the use of
primary dopaminergic (DA) neuroblasts obtained from the brain of aborted human fetuses …

The quest for new and improved therapies for Parkinson's disease (PD) remains of
paramount importance, despite previous trial failures. There is a current debate regarding …